Disease overview

Alterations

124

Molecular (A)

100

Clinical (B–E)

Direct drugs

568

Via biomarker

473

Natural agents

Natural products

Merged ranked

1037

With trial/literature evidence

Sources: Open Targets, HPO, ClinicalTrials.gov, DGIdb, ChEMBL, PubMed Literature, Seeds, GreenMedInfo · Pipeline phase 7 · Updated 2026-07-06

Remission & chronicity

Spontaneous remission

No spontaneous remission; 5-year survival Stage I: 90%; Stage III/IV: 25-30%; most patients (75%) present at Stage III-IV

Best-intervention remission

Debulking surgery + carboplatin/paclitaxel: 70-80% initial response; PARP inhibitors (olaparib, rucaparib) maintenance in BRCA-mutant: 56% 5-year PFS vs 13.8% placebo (SOLO-1); bevacizumab maintenance: modest PFS benefit; dose-dense paclitaxel: 72.1% vs 65.1% OS at 3 years

Drug-free remission

—

Relapse after remission

—

Chronicity

—

Gap size

Large — PARP inhibitors dramatically improve outcomes in BRCA-mutant patients; HRD testing not universal; no effective screening exists

Primary barrier

access + biological

Barrier detail: BRCA1/2 and HRD testing is not universal despite major impact on PARP inhibitor eligibility; bevacizumab access limited by cost; most patients are diagnosed at advanced stage due to no screening modality; CA-125 + transvaginal ultrasound screening trials (UKCTOCS) failed to show mortality reduction

Last SoC change: 2023 — mirvetuximab soravtansine (IMGN853, FRα-ADC) approved for FRα-high platinum-resistant OC; 2022 olaparib maintenance expanded; 2018 PARP inhibitor maintenance established; carboplatin/paclitaxel standard since 1990s

Remission data layers: disease_db_100 · source-locked manual data · confidence: high

Identifiers: MONDO: MONDO:0008170 · ORPHA: ORPHA:145

Alterations

Showing 80 of 124 · Types A (molecular) through E (functional)

Name	Type	Subtype	Direction	Frequency	Evidence	Sources	Links
Abdominal distention	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Abdominal pain	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Abnormality of metabolism/homeostasis	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Abnormality of the ovary	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Adult onset	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Ambiguous genitalia	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Breast carcinoma	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Dysgerminoma	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Female external genitalia in individual with 46,XY karyotype	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Gonadal calcification	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Gonadal dysgenesis with female appearance, male	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Gonadoblastoma	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Hirsutism	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Increased serum testosterone level	Lab / Clinical	Lab value	—	—	Moderate	HPO, Monarch	HPO
Ovarian gonadoblastoma	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Ovarian papillary adenocarcinoma	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
AKT1 AKT serine/threonine kinase 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ALK ALK receptor tyrosine kinase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
AR androgen receptor	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ARID1A AT-rich interaction domain 1A	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ATM ATM serine/threonine kinase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ATR ATR checkpoint kinase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
BARD1 BRCA1 associated RING domain 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
BLM BLM RecQ like helicase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
BRCA1 BRCA1 DNA repair associated	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
BRCA2 BRCA2 DNA repair associated	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
BRIP1 BRCA1 interacting DNA helicase 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CASP8 caspase 8	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CDH1 cadherin 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CDK12 cyclin dependent kinase 12	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CDKN2A cyclin dependent kinase inhibitor 2A	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CHEK2 checkpoint kinase 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CTNNB1 catenin beta 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
DICER1 dicer 1, ribonuclease III	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
DNMT3A DNA methyltransferase 3 alpha	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
DROSHA drosha ribonuclease III	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
EGFR epidermal growth factor receptor	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ERBB2 erb-b2 receptor tyrosine kinase 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ERCC5 ERCC excision repair 5, endonuclease	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ESR1 estrogen receptor 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
EXT2 exostosin glycosyltransferase 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
FANCA FA complementation group A	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
FANCC FA complementation group C	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
FANCD2 FA complementation group D2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
FBXO11 F-box protein 11	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
FGFR2 fibroblast growth factor receptor 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
FLT4 fms related receptor tyrosine kinase 4	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
FOLR1 folate receptor alpha	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
Immune response	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
KDR kinase insert domain receptor	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
KIT KIT proto-oncogene, receptor tyrosine kinase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
KRAS KRas proto-oncogene, GTPase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
MAP3K1 mitogen-activated protein kinase kinase kinase 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
MET MET proto-oncogene, receptor tyrosine kinase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
MITF melanocyte inducing transcription factor	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
MLH1 mutL homolog 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
MLLT10 MLLT10 histone lysine methyltransferase DOT1L cofactor	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
MSH2 mutS homolog 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
MSH6 mutS homolog 6	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
MUTYH mutY DNA glycosylase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NBN nibrin	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NF1 neurofibromin 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NTRK1 neurotrophic receptor tyrosine kinase 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
Overall Response Rate (ORR) (Dose Expansion Only)	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
Overall Survival	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
PALB2 partner and localizer of BRCA2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PARP1 poly(ADP-ribose) polymerase 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PARP2 poly(ADP-ribose) polymerase 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PARP3 poly(ADP-ribose) polymerase family member 3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PDGFRA platelet derived growth factor receptor alpha	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PDGFRB platelet derived growth factor receptor beta	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PIK3CA phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PIK3R1 phosphoinositide-3-kinase regulatory subunit 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PMS2 PMS1 homolog 2, mismatch repair system component	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
POLA1 DNA polymerase alpha 1, catalytic subunit	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
POLA2 DNA polymerase alpha 2, accessory subunit	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
POLD1 DNA polymerase delta 1, catalytic subunit	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
POLD2 DNA polymerase delta 2, accessory subunit	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
POLD3 DNA polymerase delta 3, accessory subunit	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
POLD4 DNA polymerase delta 4, accessory subunit	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets

Therapeutics

Direct disease associations, biomarker-linked drugs, OSMF narrative-review natural agents, merged ranking, and clinical trial / literature evidence (top agents)

Drug	Type	Phase	Evidence	Score	Trials & literature	Sources	Links
BICALUTAMIDE	Small molecule	Approved	Strong	100	3 trials 1 Trial pubs View evidence Registry trials NCT00012090 — Bicalutamide and Goserelin in Treating Patients With Cancer of the Ovary, Fallopian Tube, or Peritoneum (COMPLETED) PHASE2 NCT05647356 — The RolE oF Androgen Excess in MUscle Energy MetaboLism in Women With PolyCystic Ovary Syndrome (REFUEL PCOS) Study 2 (UNKNOWN) NA NCT03458221 — Signal TrAnsduction Pathway Activity Analysis in OVarian cancER (RECRUITING) PHASE2, PHASE3 Published literature Clinical trial publication A phase II evaluation of goserelin and bicalutamide in patients with ovarian cancer in second or higher complete clinical disease remission (Cancer, 2007) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
EPIRUBICIN	Small molecule	Approved	Strong	100	8 trials 1 Cochrane 2 Meta-analysis 50 Trial pubs 15 RCT View evidence Registry trials NCT03025477 — Two Therapeutic Strategies in First-line in Patients With Epithelial Advanced Ovarian Cancer (RECRUITING) PHASE2 NCT00025441 — Combination Chemotherapy in Treating Children With Metastatic Rhabdomyosarcoma or Other Malignant Mesenchymal Tumors (COMPLETED) PHASE2 NCT00311636 — Triptorelin in Preventing Early Menopause in Premenopausal Women Who Are Receiving Chemotherapy for Stage I, Stage II, or Stage III Breast Cancer That Has Been Removed By Surgery (COMPLETED) PHASE3 NCT00004934 — Paclitaxel and Carboplatin With or Without Epirubicin in Treating Patients With Stage IIB, Stage III, or Stage IV Invasive Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer (COMPLETED) PHASE3 NCT00003852 — Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Germ Cell Tumors (TERMINATED) PHASE2 NCT04474951 — Food Supplements Based on Nettle and Peppermint to Control Signs and Symptoms Induced by Cancer Therapies (UNKNOWN) NA NCT00722293 — A Phase I, Open-label, Study of Pazopanib in Combination With Epirubicin or Doxorubicin for Advanced Solid Tumors (COMPLETED) PHASE1 NCT02532400 — Neoadjuvant Aromatase Inhibitor(AI) With Ovarian Suppression Versus Chemotherapy in Premenopausal Breast Cancer Patients (TERMINATED) PHASE3 Published literature Cochrane review Toxicities of different first-line chemotherapy regimens in the treatment of advanced ovarian cancer: A network meta-analysis (Medicine, 2017) Meta-analysis A network meta-analysis of eight chemotherapy regimens for treatment of advanced ovarian cancer (Oncotarget, 2017) Systematic review Radiogenic angiosarcoma of the breast: case report and systematic review of the literature (BMC cancer, 2018) Systematic review Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials (BMC cancer, 2010) Systematic review [Anthracyclines in therapy of ovarian carcinoma: a systematic review of primary and 2nd-line therapy after platinum] (Zentralblatt fur Gynakologie, 2000) Clinical trial publication Association of Germline Variant Status With Therapy Response in High-risk Early-Stage Breast Cancer: A Secondary Analysis of the GeparOcto Randomized Clinical Trial (JAMA oncology, 2020) Clinical trial publication Epirubicin, Cisplatin, and Capecitabine for Primary Platinum-Resistant or Platinum-Refractory Epithelial Ovarian Cancer: Results of a Retrospective, Single-Institution Study (International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2015) Clinical trial publication First-line treatment of advanced ovarian cancer with paclitaxel/carboplatin with or without epirubicin (TEC versus TC)--a gynecologic cancer intergroup study of the NSGO, EORTC GCG and NCIC CTG (Annals of oncology : official journal of the European Society for Medical Oncology, 2012) Clinical trial publication [Gemcitabine based combination chemotherapy, a new salvage regimen for recurrent platinum resistant epithelial ovarian cancer] (Zhonghua fu chan ke za zhi, 2010) Clinical trial publication Multicenter phase 2 study of combined gemcitabine and epirubicin as second-line treatment for patients with advanced ovarian cancer (International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2010) Randomized controlled trial A phase II randomised clinical trial comparing cisplatin, paclitaxel and ifosfamide with cisplatin, paclitaxel and epirubicin in newly diagnosed advanced epithelial ovarian cancer: long-term survival analysis (British journal of cancer, 2008) Randomized controlled trial Intensified dose of cyclophosphamide with G-CSF support versus standard dose combined with platinum in first-line treatment of advanced ovarian cancer a randomised study from the GINECO group (British journal of cancer, 2007) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
SIROLIMUS	Small molecule	Approved	Strong	100	8 trials 2 Trial pubs View evidence Registry trials NCT02833506 — Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (WITHDRAWN) PHASE1 NCT00375245 — Rapamycin With Grapefruit Juice for Advanced Malignancies (COMPLETED) PHASE1 NCT03154281 — Evaluation of the Safety and Tolerability of Niraparib With Everolimus in Advanced Gynecologic Malignancies and Breast (COMPLETED) PHASE1 NCT02407509 — Phase I Trial of VS-6766 Alone and in Combination With Everolimus (COMPLETED) PHASE1 NCT00408655 — Temsirolimus, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid Tumors (COMPLETED) PHASE1 NCT01010126 — Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer (COMPLETED) PHASE2 NCT00523432 — A Phase I Study of CCI-779 (Temsirolimus) in Combination With Topotecan in Patients With Gynecologic Malignancies (COMPLETED) PHASE1 NCT03456700 — Auranofin and Sirolimus in Treating Participants With Ovarian Cancer (TERMINATED) PHASE2 Published literature Clinical trial publication A Phase 2 Trial of Protein Kinase C Iota Inhibition With the Combination of Auranofin and Sirolimus in Patients With Recurrent Ovarian Cancer (American journal of clinical oncology, 2026) Clinical trial publication mTOR inhibition modulates vaccine-induced immune responses to generate memory T cells in patients with solid tumors (Journal for immunotherapy of cancer, 2025) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
3,3',4',5-TETRACHLOROSALICYLANILIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
ABEMACICLIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ABIRATERONE ACETATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ACETAZOLAMIDE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
ACETOPHENAZINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
AFATINIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ALCLOFENAC Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
ALCLOMETASONE DIPROPIONATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
ALECTINIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ALECTINIB HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
AMCINONIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
AMDINOCILLIN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
AMIODARONE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
AMLEXANOX Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
AMLODIPINE BESYLATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
AMPHETAMINE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
ANHYDROUS TACROLIMUS Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
APALUTAMIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
APIGENIN Repurposing	Small molecule	Approved	Strong	95	2 Trial pubs 1 RCT View evidence Published literature Clinical trial publication Dietary intake of selected flavonols, flavones, and flavonoid-rich foods and risk of cancer in middle-aged and older women (The American journal of clinical nutrition, 2009) Clinical trial publication A prospective study of dietary flavonoid intake and incidence of epithelial ovarian cancer (International journal of cancer, 2007) CT.gov search · Cochrane · PubMed	DGIdb	—
APOMORPHINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ASTEMIZOLE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ATALUREN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ATEZOLIZUMAB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ATRACURIUM BESYLATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ATROPINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
AVELUMAB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
AZACITIDINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
AZARIBINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
BECLOMETHASONE DIPROPIONATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BENAZEPRIL HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
BENDAMUSTINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BENORILATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
BETAMETHASONE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BETAMETHASONE DIPROPIONATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
BETAMETHASONE SODIUM PHOSPHATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
BETAMETHASONE VALERATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
BEVACIZUMAB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BEXAROTENE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BICALUTAMIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BIFONAZOLE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BINIMETINIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BISACODYL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BITHIONOL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BITHIONOLATE SODIUM Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
BLEOMYCIN Repurposing	Small molecule	Approved	Strong	95	8 trials 2 Cochrane 2 Meta-analysis 8 RCT View evidence Registry trials NCT00276718 — Etoposide, Carboplatin, and Bleomycin in Treating Young Patients Undergoing Surgery For Malignant Germ Cell Tumors (UNKNOWN) NA NCT03067181 — Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors (RECRUITING) PHASE3 NCT00053352 — Surgery and Combination Chemotherapy in Treating Children With Extracranial Germ Cell Tumors (COMPLETED) PHASE3 NCT01042522 — Paclitaxel and Carboplatin or Bleomycin Sulfate, Etoposide Phosphate, and Cisplatin in Treating Patients With Advanced or Recurrent Sex Cord-Ovarian Stromal Tumors (UNKNOWN) PHASE2 NCT00274950 — Observation and/or Combination Chemotherapy After Surgery or Biopsy in Treating Young Patients With Extracranial Germ Cell Tumors (UNKNOWN) PHASE3 NCT00003811 — Combination Chemotherapy Plus Amifostine in Treating Children With Malignant Germ Cell Tumors (COMPLETED) PHASE2 NCT02429687 — TC or BEP in Treating Patients With Malignant Ovarian Germ Cell Tumors (RECRUITING) PHASE3 NCT02429700 — TC or BEP in Treating Patients With Ovarian Malignant Sex Cord-Stromal Tumors (RECRUITING) PHASE3 Published literature Cochrane review Role of adjuvant chemotherapy in stage IC ovarian granulosa cell tumors: a systematic review and meta-analysis (Journal of gynecologic oncology, 2025) Cochrane review Bleomycin-Induced Pneumonitis in the Treatment of Ovarian Sex Cord-Stromal Tumors: A Systematic Review and Meta-analysis (International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2015) Randomized controlled trial Results of a randomized phase II trial of paclitaxel and carboplatin versus bleomycin, etoposide and cisplatin for newly diagnosed and recurrent Chemonaive stromal ovarian tumors: An NRG oncology/gynecologic oncology group study14 (Gynecologic oncology, 2024) Randomized controlled trial Randomized trial of cisplatin and carboplatin versus cisplatin, vinblastine and bleomycin in ovarian cancer (Gynecologic and obstetric investigation, 2000) Randomized controlled trial A randomized trial of cisplatin, vinblastine, and bleomycin versus cyclophosphamide, aclacinomycin, and cisplatin in epithelial ovarian cancer (Oncology, 1997) Randomized controlled trial [Pleurodesis in malignant pleural effusion: bleomycin vs. mitoxantrone] (Pneumologie (Stuttgart, Germany), 1997) Randomized controlled trial Superiority of carboplatin monochemotherapy over carboplatin-based polychemotherapy in ovarian cancer (European journal of gynaecological oncology, 1997) CT.gov search · Cochrane · PubMed	DGIdb	—
BORTEZOMIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BOSUTINIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—

Drug	Type	Phase	Evidence	Score	Sources	Links
ALVIMOPAN	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
AMONAFIDE	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
ATEZOLIZUMAB	Biologic	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
AVELUMAB	Biologic	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
AZENOSERTIB	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
BATIRAXCEPT	Biologic	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
BENMELSTOBART	Biologic	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
CADONILIMAB	Biologic	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
CANFOSFAMIDE	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
CANFOSFAMIDE HYDROCHLORIDE	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
CATEQUENTINIB HYDROCHLORIDE	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
CEDIRANIB	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
CISPLATIN	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
CYCLOPHOSPHAMIDE	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
DOCETAXEL	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
DOSTARLIMAB	Biologic	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
DOXORUBICIN	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
DURVALUMAB	Biologic	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
EPOETIN ALFA	Biologic	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
ETARFOLATIDE	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
ETOPOSIDE	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
FARLETUZUMAB	Biologic	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
FERRIC DERISOMALTOSE	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
FERROUS GLUCONATE	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
FILGRASTIM	Biologic	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
FLUZOPARIB	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
GEMCITABINE	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
HYDRALAZINE	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
IBCASERTIB	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
IRON ISOMALTOSIDE 1000	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
IRON SUCROSE	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
ISOPHENOXODIOL	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
KARENITECIN	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
LORNOXICAM	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
LURBINECTEDIN	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
MAGNESIUM VALPROATE	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
MASITINIB	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
NEMVALEUKIN ALFA	Biologic	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
NINTEDANIB	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
NIVOLUMAB	Biologic	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets

Drug	Type	Phase	Evidence	Score	Trials & literature	Sources	Links
3,3',4',5-TETRACHLOROSALICYLANILIDE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
ABEMACICLIB Repurposing via CDKN2A	Small molecule	Approved	Strong	95	—	DGIdb	—
ABIRATERONE ACETATE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
ACETAZOLAMIDE Repurposing via AKT1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
ACETOPHENAZINE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
AFATINIB Repurposing via ALK	Small molecule	Approved	Strong	95	—	DGIdb	—
ALCLOFENAC Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
ALCLOMETASONE DIPROPIONATE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
ALECTINIB Repurposing via ALK	Small molecule	Approved	Strong	95	—	DGIdb	—
ALECTINIB HYDROCHLORIDE Repurposing via ALK	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
AMCINONIDE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
AMDINOCILLIN Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
AMIODARONE HYDROCHLORIDE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
AMLEXANOX Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
AMLODIPINE BESYLATE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
AMPHETAMINE Repurposing via AKT1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
ANHYDROUS TACROLIMUS Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
APALUTAMIDE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
APIGENIN Repurposing via BRCA1	Small molecule	Approved	Strong	95	2 Trial pubs 1 RCT View evidence Published literature Clinical trial publication Dietary intake of selected flavonols, flavones, and flavonoid-rich foods and risk of cancer in middle-aged and older women (The American journal of clinical nutrition, 2009) Clinical trial publication A prospective study of dietary flavonoid intake and incidence of epithelial ovarian cancer (International journal of cancer, 2007) CT.gov search · Cochrane · PubMed	DGIdb	—
APOMORPHINE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
ASTEMIZOLE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
ATALUREN Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
ATEZOLIZUMAB Repurposing via ARID1A	Small molecule	Approved	Strong	95	—	DGIdb	—
ATRACURIUM BESYLATE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
ATROPINE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
AVELUMAB Repurposing via ATM	Small molecule	Approved	Strong	95	—	DGIdb	—
AZACITIDINE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
AZARIBINE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
BECLOMETHASONE DIPROPIONATE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
BENAZEPRIL HYDROCHLORIDE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
BENDAMUSTINE Repurposing via ATM	Small molecule	Approved	Strong	95	—	DGIdb	—
BENORILATE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
BETAMETHASONE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
BETAMETHASONE DIPROPIONATE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
BETAMETHASONE SODIUM PHOSPHATE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
BETAMETHASONE VALERATE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
BEVACIZUMAB Repurposing via ALK	Small molecule	Approved	Strong	95	—	DGIdb	—
BEXAROTENE Repurposing via BLM	Small molecule	Approved	Strong	95	—	DGIdb	—
BICALUTAMIDE Repurposing via CDH1	Small molecule	Approved	Strong	95	—	DGIdb	—
BICALUTAMIDE Repurposing via AKT1	Small molecule	Approved	Strong	95	3 trials 1 Trial pubs View evidence Registry trials NCT00012090 — Bicalutamide and Goserelin in Treating Patients With Cancer of the Ovary, Fallopian Tube, or Peritoneum (COMPLETED) PHASE2 NCT05647356 — The RolE oF Androgen Excess in MUscle Energy MetaboLism in Women With PolyCystic Ovary Syndrome (REFUEL PCOS) Study 2 (UNKNOWN) NA NCT03458221 — Signal TrAnsduction Pathway Activity Analysis in OVarian cancER (RECRUITING) PHASE2, PHASE3 Published literature Clinical trial publication A phase II evaluation of goserelin and bicalutamide in patients with ovarian cancer in second or higher complete clinical disease remission (Cancer, 2007) CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL Open Targets

Natural Products

77 natural products with the same evidence schema as repurposed drugs — registry trials, PubMed literature, and reference links (pipeline-ranked)

Reference lookups: GreenMedInfo · Examine.com

Drug	Type	Phase	Evidence	Score	Trials & literature	Sources	Links
Vitamin D3 Natural product Meta-analysis Effect of 1α,25(OH)(2)D(3)-Treated M1 and M2 Macrophages on Cell Prolif… Meta Analysis Review: there is a consistently strong inverse correlations with solar… Human Study In this cohort, higher serum 25(OH)D concentrations at diagnosis were a…	Nutraceutical	Approved	Emerging	10	8 trials 1 Meta-analysis View evidence Registry trials NCT00743574 — Health Benefits of Vitamin D and Calcium in Women With PCOS (Polycystic Ovarian Syndrome) (COMPLETED) NA NCT04670393 — Antioxidant Supplement Associated With Oral Probiotics in Patients With PCOS in IVF (COMPLETED) NA NCT06101147 — Effect of Vitamin D Supplementation on Testosterone Level in Women With Polycystic Ovary Syndrome (COMPLETED) PHASE2 NCT02656121 — Correction of Vitamin D Deficiency and Its Effect on Ovulation Induction in Women With PCOS (VIDEO): A Feasibility RCT (COMPLETED) PHASE2 NCT01744821 — Vitamin D for Women at Increased Risk of Developing Ovarian, Fallopian, or Primary Peritoneal Cancer (TERMINATED) NA NCT05101811 — Vitamin D Levels in Women With Polycystic Ovary Syndrome (COMPLETED) PHASE4 NCT06158932 — A Single Group Study to Evaluate the Effects of a Myo-Inositol and D-Chiro Inositol Supplement on Symptoms Associated With Polycystic Ovary Syndrome and Hormone Imbalance (COMPLETED) NA NCT00022087 — Zoledronate, Calcium, and Vitamin D in Preventing Bone Loss in Women Receiving Adjuvant Chemotherapy for Breast Cancer (COMPLETED) PHASE3 Published literature Meta-analysis Effect of 1α,25(OH)(2)D(3)-Treated M1 and M2 Macrophages on Cell Proliferation and Migration Ability in Ovarian Cancer (Nutrition and cancer, 2022) CT.gov search · Cochrane · PubMed	GreenMedInfo	PubChem GreenMedInfo
Omega-3 Fatty Acids Natural product Cochrane review Gynecological cancer and omega-3 fatty acid intakes: Meta-analysis Cochrane review Dietary Intake of Omega-3 fatty acids and Endocrine-related Gynecologic… Cochrane review Effects of omega-3 fatty acids on cancer risk: a systematic review	Nutraceutical	Phase II	Emerging	10	8 trials 3 Cochrane 2 Meta-analysis 1 Trial pubs 1 RCT View evidence Registry trials NCT06545721 — Weight Cycling on Hyperandrogenemia and Insulin Resistance in Polycystic Ovary Syndrome (RECRUITING) NA NCT05597111 — Comparison of Docosahexaenoic (DHA) Values in Patients With Polycystic Ovary Syndrome (PCOS) (UNKNOWN) NCT07036952 — Effect of Omega-3 Supplementation as Add on Therapy on Metabolic Syndrome in Women With Polycystic Ovary Syndrome. (ENROLLING_BY_INVITATION) NA NCT01766557 — Assessment of Cod Protein as an Insulin-sensitizing Agent in Women With Polycystic Ovary Syndrome. (COMPLETED) NA NCT04116203 — Dietary Fish Oil Intervention in Polycystic Ovary Syndrome (PCOS) (COMPLETED) PHASE1 NCT07604870 — Krill Oil and Metformin in Women With PCOS and Metabolically Unhealthy Obesity (COMPLETED) PHASE2 NCT03306745 — Micronutrient Supplementation in PCO-syndrome (COMPLETED) NA NCT01189669 — n-3 Polyunsaturated Fatty Acids (PUFA) Supplementation in Young Women With Polycystic Ovary Syndrome (PCOS) (COMPLETED) NA Published literature Cochrane review Gynecological cancer and omega-3 fatty acid intakes: Meta-analysis (Asia Pacific journal of clinical nutrition, 2021) Cochrane review Dietary Intake of Omega-3 fatty acids and Endocrine-related Gynecological Cancer: A Meta-Analysis of Observational Studies (Cancer research and treatment, 2019) Cochrane review Effects of omega-3 fatty acids on cancer risk: a systematic review (JAMA, 2006) Clinical trial publication Flaxseed enriched diet-mediated reduction in ovarian cancer severity is correlated to the reduction of prostaglandin E(2) in laying hen ovaries (Prostaglandins, leukotrienes, and essential fatty acids, 2013) CT.gov search · Cochrane · PubMed	GreenMedInfo	PubChem GreenMedInfo
Vitamin C Natural product Cochrane review Systematic Review of Intravenous Ascorbate in Cancer Clinical Trials Systematic review Dietary intake and ovarian cancer risk: a systematic review Clinical trial publication An open-label, phase II multicohort study of an oral hypomethylating ag…	Nutraceutical	Approved	Emerging	10	5 trials 1 Cochrane 1 Meta-analysis 2 Trial pubs 1 RCT View evidence Registry trials NCT01953107 — Oral Iron vs. Placebo in Newly Diagnosed Gynecologic Oncology Patients Who Are Surgical Candidates. (COMPLETED) PHASE4 NCT00228319 — Treatment of Newly Diagnosed Ovarian Cancer With Antioxidants (COMPLETED) PHASE1, PHASE2 NCT03049462 — The Physiological Responses and Adaptation of Brown Adipose Tissue to Chronic Treatment With Beta3-Adrenergic Receptor Agonists (RECRUITING) PHASE1 NCT00284427 — Safety of Antioxidants During GYN Cancer Care (COMPLETED) PHASE2 NCT00593294 — Oral Contraceptive and Cardiovascular Risk in PCOS (COMPLETED) PHASE4 Published literature Cochrane review Systematic Review of Intravenous Ascorbate in Cancer Clinical Trials (Antioxidants (Basel, Switzerland), 2018) Systematic review Dietary intake and ovarian cancer risk: a systematic review (Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2014) Clinical trial publication An open-label, phase II multicohort study of an oral hypomethylating agent CC-486 and durvalumab in advanced solid tumors (Journal for immunotherapy of cancer, 2020) Clinical trial publication High-dose parenteral ascorbate enhanced chemosensitivity of ovarian cancer and reduced toxicity of chemotherapy (Science translational medicine, 2014) CT.gov search · Cochrane · PubMed	GreenMedInfo	PubChem GreenMedInfo
Ginger Natural product Cochrane review Modulatory Effects of Gingerol in Cancer Cell Growth Through Activation… Animal Study, In Vitro Study The inhibitory effect of 6-gingerol and cisplatin on ovarian cancer and… In Vitro Study 10-gingerol inhibits ovarian cancer cell growth by inducing G2 arrest.	Botanical	Preclinical	Emerging	10	2 trials 1 Cochrane View evidence Registry trials NCT05875233 — A Study to Evaluate the Effect of Elix Cycle Balance and Daily Harmony on Polycystic Ovary Syndrome (ACTIVE_NOT_RECRUITING) NA NCT03493984 — Plant Exosomes and Patients Diagnosed With Polycystic Ovary Syndrome (PCOS) 17 (WITHDRAWN) NA Published literature Cochrane review Modulatory Effects of Gingerol in Cancer Cell Growth Through Activation and Suppression of Signal Pathways in Cancer Cell Growth Systemic Review (Journal of pharmacy & bioallied sciences, 2024) CT.gov search · Cochrane · PubMed	GreenMedInfo	PubChem GreenMedInfo
Curcumin Natural product Systematic review The Association Between Anti-Neoplastic Effects of Curcumin and Urogeni… Animal Study, In Vitro Study Co-delivery of docetaxel and curcumin via nanomicelles for enhancing an… Animal Study Curcumin enhances oral bioavailability and anti-tumor therapeutic effic…	Food compound	Phase III	Emerging	7	3 trials 1 Cochrane View evidence Registry trials NCT07278128 — Evaluation of the Therapeutic Effects of Curcumin on Changes in Lipid, Metabolic, and Hormonal Profiles, Liver Enzyme Activity, and Ultrasonography Morphology of the Liver in Women With Polycystic Ovary Syndrome and Nonalcoholic Fatty Liver Disease: A Double-blind, Placebo-controlled Clinical Trial (COMPLETED) PHASE2, PHASE3 NCT05306002 — Nutritional Intervention and DNA Damage of Patients With HBOC (COMPLETED) NA NCT06551285 — Study of the Effect of a Nutritional Supplement on Microbiota, Metabolic Control, Inflammatory Profile, and Quality of Life in Patients With Polycystic Ovary Syndrome. (RECRUITING) NA Published literature Systematic review The Association Between Anti-Neoplastic Effects of Curcumin and Urogenital Cancers: A Systematic Review (BioMed research international, 2024) CT.gov search · Cochrane · PubMed	GreenMedInfo	PubChem GreenMedInfo
Berberine Natural product Nanocrystalline berberine is associated with improved antitumor activit… Natural compounds in ovarian cancer: mechanistic insights and therapeut… Recent Update Targeting Autophagy-Apoptosis Crosstalk Using Bioactive N…	Botanical	Preclinical	Emerging	7	5 trials View evidence Registry trials NCT07465575 — Berberine Phytosome for Signs and Symptoms of Polycystic Ovary Syndrome (PCOS) (NOT_YET_RECRUITING) NA NCT01116167 — Polycystic Ovary Syndrome (PCOS): Effect Of Letrozole and Berberine (UNKNOWN) NA NCT04932070 — Berberine and Polycystic Ovary Syndrome (COMPLETED) NA NCT05480670 — Treatment Benefits of Berberine Supplementation for Women With PCOS (COMPLETED) NA NCT01138930 — Effect of Berberine on Hormonal and Metabolic Features in Obese Women With Polycystic Ovary Syndrome (PCOS) (UNKNOWN) NA CT.gov search · Cochrane · PubMed	GreenMedInfo	PubChem GreenMedInfo
Quercetin Natural product Cochrane review Quercetin and ovarian cancer: An evaluation based on a systematic review Systematic review Selected Flavonols in Breast and Gynecological Cancer: A Systematic Rev… Systematic review The pharmacological mechanism of Chinese herbs effective in treating ad…	Food compound	Phase II	Emerging	7	1 trials 1 Cochrane 3 Trial pubs 1 RCT View evidence Registry trials NCT07182526 — Effects of Adding Quercetin or Alpha Lipoic Acid to Usual Care on Symptoms and Blood Markers in Iraqi Women With Polycystic Ovary Syndrome (RECRUITING) PHASE2 Published literature Cochrane review Quercetin and ovarian cancer: An evaluation based on a systematic review (Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences, 2016) Systematic review Selected Flavonols in Breast and Gynecological Cancer: A Systematic Review (Nutrients, 2023) Systematic review The pharmacological mechanism of Chinese herbs effective in treating advanced ovarian cancer: Integrated meta-analysis and network pharmacology analysis (Frontiers in pharmacology, 2022) CT.gov search · Cochrane · PubMed	GreenMedInfo	PubChem GreenMedInfo
Resveratrol Natural product Cochrane review Phytochemicals as Adjunctive with Conventional Anticancer Therapies Animal Study Integrative transcriptomics and structure-based screening identifies Ph… Animal Study Myricetin suppresses TGF-β-induced epithelial-to-mesenchymal transition…	Food compound	Approved	Emerging	7	5 trials 1 Cochrane View evidence Registry trials NCT01720459 — Effects of Micronized Trans-resveratrol Treatment on Polycystic Ovary Syndrome (PCOS) Patients (UNKNOWN) NA NCT04867252 — Effects of Combined Resveratrol and Myo-inositol on Altered Metabolic, Endocrine Parameters and Perceived Stress in Patients With Polycystic Ovarian Syndrome (COMPLETED) PHASE2 NCT05306002 — Nutritional Intervention and DNA Damage of Patients With HBOC (COMPLETED) NA NCT01489319 — Evaluation of Oral Lipid Ingestion in Relation to Ovarian Androgen Secretion in Polycystic Ovary Syndrome (PCOS) (TERMINATED) PHASE1 NCT02766803 — Effects of Simvastatin and Micronized Trans-resveratrol Treatment on Polycystic Ovary Syndrome (PCOS) Patients (UNKNOWN) PHASE4 Published literature Cochrane review Phytochemicals as Adjunctive with Conventional Anticancer Therapies (Current pharmaceutical design, 2016) CT.gov search · Cochrane · PubMed	GreenMedInfo	PubChem GreenMedInfo
Ashwagandha Natural product Animal Study Withaferin A and ovarian cancer antagonistically regulate skeletal musc… Animal Study Withaferin A attenuates ovarian cancer-induced cardiac cachexia. In Vitro Study Withaferin A ameliorates ovarian cancer-induced cachexia and proinflamm…	Ayurvedic	Phase II	Emerging	7	1 trials View evidence Registry trials NCT05610735 — Combination Therapy for Recurrent Ovarian Cancer (RECRUITING) PHASE1, PHASE2 CT.gov search · Cochrane · PubMed	GreenMedInfo	PubChem GreenMedInfo
Egcg Natural product Cochrane review Can green tea do that? A literature review of the clinical evidence Clinical trial publication A two-stage, single-arm, phase II study of EGCG-enriched green tea drin… Meta Analysis This meta-analysis showed an inverse association between tea consumptio…	Food compound	Preclinical	Emerging	7	1 Cochrane 1 Trial pubs View evidence Published literature Cochrane review Can green tea do that? A literature review of the clinical evidence (Preventive medicine, 2009) Clinical trial publication A two-stage, single-arm, phase II study of EGCG-enriched green tea drink as a maintenance therapy in women with advanced stage ovarian cancer (Gynecologic oncology, 2013) CT.gov search · Cochrane · PubMed	GreenMedInfo	PubChem GreenMedInfo
Melatonin Natural product Clinical trial publication Individual variations in serum melatonin levels through time: implicati… Clinical trial publication A phase II study of tamoxifen plus melatonin in metastatic solid tumour… Human Study Lower serum levels of melatonin in ovarian cancer patients which may co…	Nutraceutical	Approved	Emerging	7	4 trials 2 Trial pubs 1 RCT View evidence Registry trials NCT04670393 — Antioxidant Supplement Associated With Oral Probiotics in Patients With PCOS in IVF (COMPLETED) NA NCT00988078 — Effects of Metformin and Oral Hormonal Contraceptive in Adolescents With Polycystic Ovary Syndrome (UNKNOWN) NA NCT01540747 — Role of Melatonin Supplementation in Follicular Fluid of in Vitro Fertilization (IVF) Patients With Polycystic Ovarian Syndrome (COMPLETED) PHASE4 NCT02663570 — Effects of Melatonin in PCOS Women (UNKNOWN) NA Published literature Clinical trial publication Individual variations in serum melatonin levels through time: implications for epidemiologic studies (PloS one, 2013) Clinical trial publication A phase II study of tamoxifen plus melatonin in metastatic solid tumour patients (British journal of cancer, 1996) CT.gov search · Cochrane · PubMed	GreenMedInfo	PubChem GreenMedInfo
Grape Seed Extract Natural product Anti-proliferative and anti-apoptotic effects of grape seed extract on…	Botanical	Preclinical	Emerging	7	1 pubs View evidence CT.gov search · Cochrane · PubMed	GreenMedInfo	GreenMedInfo
Bitter Melon Natural product Animal Study, In Vitro Study Bitter melon extract functions as a natural AMPK activator in the inhib… Animal Study MAP30 protein from Momordica charantia is therapeutic and has synergic…	Botanical	Preclinical	Emerging	7	7 pubs View evidence CT.gov search · Cochrane · PubMed	GreenMedInfo	GreenMedInfo
Saffron Natural product The effects of crocetin, extracted from saffron, in chemotherapy agains… Crocin suppresses multidrug resistance in MRP overexpressing ovarian ca… Crocetin induces cytotoxicity and enhances vincristine-induced cancer c…	Botanical	Preclinical	Emerging	7	1 trials View evidence Registry trials NCT02458001 — Developing a Stepped Approach to Improving Sexual Function aFteR Treatment fOr gyNaecological Cancer (UNKNOWN) NA CT.gov search · Cochrane · PubMed	GreenMedInfo	PubChem GreenMedInfo
Schisandra Natural product Human Study A combination of Leuzea carthamoides (Maral root), Rhodiola, Eleutheroc…	TCM herb	Preclinical	Emerging	7	6 pubs View evidence CT.gov search · Cochrane · PubMed	GreenMedInfo	GreenMedInfo
Selenium Natural product Clinical trial publication Efficacy and safety of intravenous administration of high-dose selenium… Clinical trial publication Phase I trial of selenium plus chemotherapy in gynecologic cancers Clinical trial publication Selenium as an element in the treatment of ovarian cancer in women rece…	Nutraceutical	Phase III	Emerging	7	6 trials 6 Trial pubs 1 RCT View evidence Registry trials NCT04670393 — Antioxidant Supplement Associated With Oral Probiotics in Patients With PCOS in IVF (COMPLETED) NA NCT03673995 — Myoinositol Plus L-tyrosine, Selenium and Chromium in PCOS (COMPLETED) NA NCT05672095 — Niraparib and Selenium for the Treatment of Recurrent BRCA Negative Platinum Resistant Ovarian Cancer (WITHDRAWN) PHASE1, PHASE2 NCT05306002 — Nutritional Intervention and DNA Damage of Patients With HBOC (COMPLETED) NA NCT03306745 — Micronutrient Supplementation in PCO-syndrome (COMPLETED) NA NCT04201561 — High Dose Inorganic Selenium for Preventing Chemotherapy Induced Peripheral Neuropathy (UNKNOWN) PHASE3 Published literature Clinical trial publication Efficacy and safety of intravenous administration of high-dose selenium for preventing chemotherapy-induced peripheral neuropathy in platinum-sensitive recurrent ovarian cancer: a phase 3, double-blind, parallel group, randomized controlled pilot study (BMC medicine, 2026) Clinical trial publication Phase I trial of selenium plus chemotherapy in gynecologic cancers (Gynecologic oncology, 2018) Clinical trial publication Selenium as an element in the treatment of ovarian cancer in women receiving chemotherapy (Gynecologic oncology, 2004) Clinical trial publication Protective role of selenium against the toxicity of multi-drug chemotherapy in patients with ovarian cancer (Die Pharmazie, 2000) Clinical trial publication Selenium (Se) deficiency in women with ovarian cancer undergoing chemotherapy and the influence of supplementation with this micro-element on biochemical parameters (Die Pharmazie, 1998) CT.gov search · Cochrane · PubMed	GreenMedInfo	PubChem GreenMedInfo
Cannabidiol Natural product Human Study A case report of a female patient who demonstrated disease response aft… Animal Study Cannabidiol inhibits epithelial ovarian cancer: role of gut microbiome. In Vitro Study Enhancing ovarian cancer conventional chemotherapy through the combinat…	Food compound	Phase I	Emerging	2	1 trials View evidence Registry trials NCT05410717 — CLDN6/GPC3/Mesothelin/AXL-CAR-NK Cell Therapy for Advanced Solid Tumors (RECRUITING) PHASE1 CT.gov search · Cochrane · PubMed	GreenMedInfo	PubChem GreenMedInfo
Flavonoids Natural product Cochrane review Dietary Flavonoids Consumption and Health: An Umbrella Review Meta-analysis Association between dietary intake and risk of ovarian cancer: a system… Meta-analysis Association among Dietary Flavonoids, Flavonoid Subclasses and Ovarian…	Nutraceutical	Phase II	Emerging	0	1 trials 1 Cochrane 2 Meta-analysis 2 Trial pubs 1 RCT View evidence Registry trials NCT07182526 — Effects of Adding Quercetin or Alpha Lipoic Acid to Usual Care on Symptoms and Blood Markers in Iraqi Women With Polycystic Ovary Syndrome (RECRUITING) PHASE2 Published literature Cochrane review Dietary Flavonoids Consumption and Health: An Umbrella Review (Molecular nutrition & food research, 2024) Meta-analysis Association between dietary intake and risk of ovarian cancer: a systematic review and meta-analysis (European journal of nutrition, 2021) Meta-analysis Association among Dietary Flavonoids, Flavonoid Subclasses and Ovarian Cancer Risk: A Meta-Analysis (PloS one, 2016) Systematic review Dietary intake and ovarian cancer risk: a systematic review (Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2014) Clinical trial publication Dietary intake of selected flavonols, flavones, and flavonoid-rich foods and risk of cancer in middle-aged and older women (The American journal of clinical nutrition, 2009) Clinical trial publication A prospective study of dietary flavonoid intake and incidence of epithelial ovarian cancer (International journal of cancer, 2007) CT.gov search · Cochrane · PubMed	GreenMedInfo	GreenMedInfo
Ginsenosides Natural product Cochrane review Phytochemicals as Adjunctive with Conventional Anticancer Therapies Animal Study, In Vitro Study Combining Rp1 with chemotherapeutic agents could circumvent drug resist… Animal Study, In Vitro Study Ginsenoside 20(S)-Rg3 inhibited the Warburg effect in ovarian cancer ce…	Nutraceutical	Preclinical	Emerging	0	1 Cochrane View evidence Published literature Cochrane review Phytochemicals as Adjunctive with Conventional Anticancer Therapies (Current pharmaceutical design, 2016) CT.gov search · Cochrane · PubMed	GreenMedInfo	GreenMedInfo
Apigenin Natural product Dietary intake of selected flavonols, flavones, and flavonoid-rich food…	Food compound	Preclinical	Emerging	0	No indexed hits View evidence CT.gov search · Cochrane · PubMed	GreenMedInfo	PubChem GreenMedInfo
Genistein Natural product Human Study Fermented soy therapy may have therapeutic value in treating platinum-r… Animal Study Genistein suppresses the inflammation and GSK-3 pathway in an animal mo… In Vitro Study "Genistein, a soy phytoestrogen, prevents the growth of BG-1 ovari…	Food compound	Preclinical	Emerging	0	—	GreenMedInfo	PubChem GreenMedInfo
Caffeic Acid Phenethyl Ester Natural product Animal Study, In Vitro Study Caffeic acid phenethyl ester inhibits the progression of ovarian cancer. Animal Study, In Vitro Study Phenethyl isothiocyanate hampers growth and progression of HER2-positiv…	Food compound	Preclinical	Emerging	0	—	GreenMedInfo	PubChem GreenMedInfo
Shikonin Natural product Animal Study Shikonin mediates apoptosis through G protein-coupled estrogen receptor… Animal Study, In Vitro Study TEM1-targeting PEGylated PLGA shikonin nanoformulation for immunomodula…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Cardamonin Natural product	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Baicalein Natural product Wogonin and its analogs for the prevention and treatment of cancer: A s…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Cruciferous Vegetables Natural product Meta Analysis Consumption of cruciferous vegetables may reduce the risk of ovarian ca… Human Study A diet that includes cruciferous vegetables could be an important modif… Human Study Pre-diagnosis cruciferous vegetables and isothiocyanates intake and ova…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Myricetin Natural product Animal Study, In Vitro Study Effect of gallic acid and myricetin on ovarian cancer models. Animal Study, In Vitro Study Myricetin might serve as potential anti-angiogenic agent in the prevent… Animal Study Myricetin suppresses TGF-β-induced epithelial-to-mesenchymal transition…	Food compound	Preclinical	Emerging	0	—	GreenMedInfo	PubChem GreenMedInfo
Citrus Naringin Natural product Animal Study, In Vitro Study Naringin inhibits cisplatin resistance of ovarian cancer cells. Animal Study Naringin inhibits ovarian tumor growth by promoting apoptosis. Animal Study Reversal of platinum-based chemotherapy resistance in ovarian cancer by…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Flaxseed Natural product Animal Study Flaxseed has a chemopreventive effect on ovarian cancer and increased s… Animal Study Flaxseed increases animal lifespan and reduces ovarian cancer severity… Animal Study Flaxseed reduces the pro-carcinogenic micro-environment in the ovaries…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Naringenin Natural product Animal Study Naringenin suppresses epithelial ovarian cancer by inhibiting prolifera…	Food compound	Preclinical	Emerging	0	—	GreenMedInfo	PubChem GreenMedInfo
Ellagic Acid Natural product Animal Study, In Vitro Study Pharmacological effects of natural components against ovarian cancer an… Animal Study, In Vitro Study The main components of pomegranate can inhibit metastasis of ovarian ca… In Vitro Study The anti-tumourigenic effect of ellagic acid in SKOV-3 ovarian cancer c…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Betulinic Acid Natural product Programmed-response cross-linked nanocarrier for multidrug-resistant ov… Rhodamine 101 Conjugates of Triterpenoic Amides Are of Comparable Cytot… Betulinic acid and its spray dried microparticle formulation: In vitro…	Food compound	Preclinical	Emerging	0	—	GreenMedInfo	PubChem GreenMedInfo
Chrysin Natural product Chrysin-Loaded Micelles Regulate Cell Cycle and Induce Intrinsic and Ex… Inhibition of DNA polymerase eta-mediated translesion DNA synthesis wit… Niosomes nanoparticles as a novel approach in drug delivery enhances an…	Food compound	Preclinical	Emerging	0	—	GreenMedInfo	PubChem GreenMedInfo
Cranberry Natural product	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Salvia Miltiorrhiza Natural product Dimethyl bisphenolate inhibits ovarian cancer growth by regulating the… Dihydrotanshinone I inhibits ovarian tumor growth by suppressing ITGB1/… Preliminary exploration of the potential role of salvianolic acid F in…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Delphinidin Natural product The multiple actions of grape and its polyphenols on female reproductiv… Delphinidin Increases the Sensitivity of Ovarian Cancer Cell Lines to 3… Delphinidin inhibits BDNF-induced migration and invasion in SKOV3 ovari…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Black Tea Natural product Meta Analysis This meta-analysis showed an inverse association between tea consumptio… Human Study Higher intakes of flavonols and flavanones as well as black tea consump…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Daidzein Natural product Human Study Fermented soy therapy may have therapeutic value in treating platinum-r… Animal Study, In Vitro Study Daidzein exerts anticancer activity towards SKOV3 human ovarian cancer…	Food compound	Preclinical	Emerging	0	—	GreenMedInfo	PubChem GreenMedInfo
Soy Natural product Human Study Fermented soy therapy may have therapeutic value in treating platinum-r… Human Study Soy intake has a protective effect against the risk for endocrine-relat…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Isoliquiritigenin Natural product Human In Vitro Isoliquiritigenin is a candidate agent for the treatment of human ovari… Animal Study, In Vitro Study Isoliquiritigenin may be an effective therapeutic agent against ovarian…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Ursolic Acid Natural product Human In Vitro Ursolic acid could affect the proliferation and apoptosis of human ovar…	Food compound	Preclinical	Emerging	0	—	GreenMedInfo	PubChem GreenMedInfo
Gallic Acid Natural product Animal Study, In Vitro Study Effect of gallic acid and myricetin on ovarian cancer models.	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Gambogic Acid Natural product Animal Study, In Vitro Study Gambogic acid sensitizes ovarian cancer cells to doxorubicin through RO… Animal Study Gambogic acid induces GSDME dependent pyroptotic signaling pathway via…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Plumbagin Natural product Animal Study, In Vitro Study Plumbagin inhibits tumorigenesis and angiogenesis of ovarian cancer cel…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Amla Fruit Natural product Animal Study, In Vitro Study Amla extract may prove useful as an alternative or adjunct therapeutic… Animal Study, In Vitro Study Amla extract modulates cancer cells and the tumor microenvironment.	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Mangiferin Natural product Animal Study Anti-neoplastic effect of mangiferin on human ovarian adenocarcinoma OV… Animal Study, In Vitro Study Pharmacological effects of natural components against ovarian cancer an…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Organosulfur Compounds Natural product Animal Study Effects of diallyl disulfide on the proliferation and apoptosis of epit… Animal Study Integrative transcriptomics and structure-based screening identifies Ph…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Fisetin Natural product Animal Study, In Vitro Study Fisetin and fisetin nanopartical have the effect of anti-ovarian cancer… Animal Study, In Vitro Study This is the first insight into the antitumor, anti-proliferative and th…	Food compound	Preclinical	Emerging	0	—	GreenMedInfo	PubChem GreenMedInfo
Gold (Nanoparticles) Natural product Animal Study, In Vitro Study Gold nanoparticles sensitize ovarian cancer cells to cisplatin. Animal Study Synergetic delivery of artesunate and isosorbide 5-mononitrate with red…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Sophora Flavescens Natural product Animal Study Oxymatrine suppresses proliferation and facilitates apoptosis of human… Animal Study PLGA-PEG-c(RGDfK)- Kushenol E micelles with a therapeutic potential for…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Luteolin Natural product Animal Study, In Vitro Study Pharmacological effects of natural components against ovarian cancer an… Animal Study, In Vitro Study The main components of pomegranate can inhibit metastasis of ovarian ca…	Food compound	Preclinical	Emerging	0	—	GreenMedInfo	PubChem GreenMedInfo
Artesunate Natural product Animal Study Synergetic delivery of artesunate and isosorbide 5-mononitrate with red…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Raspberry Natural product In Vitro Study A red raspberry component, sanguiin H-6 could inhibit A2780 human ovari…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Artemisinin Natural product	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Astragaloside Natural product Chiral and Dual Drugs Combination Reduces Tumor-Associated Neutrophils-… AS-IV inhibits the progression of ovarian cancer by targeting the circ_… Astragaloside II enhanced sensitivity of ovarian cancer cells to cispla…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Barberry Natural product	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Beta-Elemene Natural product RETRACTION: Treatment with β-elemene combined with paclitaxel inhibits… Therapeutic potential of Curcuma oil and its terpenoids in gynecologica… Treatment with β-elemene combined with paclitaxel inhibits growth, migr…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Cucurbitacin B Natural product Label-free-based quantitative proteomic analysis of the inhibition of c… Inhibition of paclitaxel resistance and apoptosis induction by cucurbit… Approach for chemosensitization of cisplatin-resistant ovarian cancer b…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Demethoxycurcumin Natural product Effects of Curcumin and Its Analogue Desmethoxycurcumin on miR-133b and… Demethoxycurcumin inhibited human epithelia ovarian cancer cells' growt… Cytotoxicity of curcuminoids and some novel compounds from Curcuma zedo…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
EGCG (Epigallocatechin Gallate) Natural product	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Emodin Natural product Novel Aloe-Emodin Derivatives as Potential Anticancer Agents: Synthesis… Comprehensive analysis of VDAC1 in gynecological tumors and structure-b… Emd-D inhibited ovarian cancer progression via PFKFB4-dependent glycoly…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Gc Protein-Derived Macrophage Activating Factor (GcMAF) Natural product Human Study The clinical cases presented here reinforce the hypothesis that GcMAF c… Meta Analysis Serum C-reactive protein levels may serve as an indicator of ovarian ca… Human Study A diet that includes cruciferous vegetables could be an important modif…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Ginseng (Siberian) Natural product Human Study A combination of Leuzea carthamoides (Maral root), Rhodiola, Eleutheroc…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Maral Root Natural product Human Study A combination of Leuzea carthamoides (Maral root), Rhodiola, Eleutheroc…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Rhodiola (Tibetan Ginseng) Natural product Human Study A combination of Leuzea carthamoides (Maral root), Rhodiola, Eleutheroc…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Agaricus Blazei Natural product Human Study Agaricus blazei increases natural killer cell activity and quality of l…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Isoflavones Natural product Human Study Fermented soy therapy may have therapeutic value in treating platinum-r…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Anthocyanins Natural product Human Study Higher intakes of flavonols and flavanones as well as black tea consump…	Food compound	Preclinical	Emerging	0	—	GreenMedInfo	PubChem GreenMedInfo
Mistletoe Natural product Human Study Mistletoe may prolong overall survival of ovarian cancer patients.	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Fiber Natural product Human Study Modifiable lifestyle factors and ovarian cancer incidence in women.	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Fruit: All Natural product Human Study Modifiable lifestyle factors and ovarian cancer incidence in women.	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Rice Natural product Human Study Modifiable lifestyle factors and ovarian cancer incidence in women.	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Vegetables: All Natural product Human Study Modifiable lifestyle factors and ovarian cancer incidence in women. Meta Analysis Consumption of cruciferous vegetables may reduce the risk of ovarian ca… Human Study A diet that includes cruciferous vegetables could be an important modif…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Infection/Infectitious Agent Byproducts (Beneficial) Natural product Human Study Mumps parotitis may lead to expression and immune recognition of a tumo… Human In Vitro Isoliquiritigenin is a candidate agent for the treatment of human ovari… Human In Vitro Ursolic acid could affect the proliferation and apoptosis of human ovar…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Olive Natural product Human Study Olive oil consumption is associated with reduced incidence of ovarian c… Animal Study Olive oil prevents bone loss in tumor patients and has excellent prospe…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Tocotrienol: Delta Natural product Human Study The combination of bevacizumab and tocotrienol is potent in chemotherap…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Coffee Natural product Human Study These results suggest that coffee drinking may protect against liver, o…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo

Alterations and therapeutics are aggregated from public databases (Open Targets, HPO, ChEMBL, DGIdb, and others). Natural agents are candidates from OSMF narrative reviews on opensourcemed.info/chronic-disease.html — not approved treatments. This page is for research orientation only — not medical advice.

Disease overview

Remission & chronicity

Alterations

Therapeutics

Natural Products

Part of the Open Source Medicine Foundation Network